Arvinas adds to momentum with Bayer deal for protein degraders
Arvinas is building on its recent momentum by signing Bayer as its fourth pharma partner in a deal announced Tuesday that aims to broaden its pipeline of protein degraders into new indications. The partnership comes in a 14-month span that has seen the biotech raise $185 million in a series C and IPO, partner with Pfizer and bring its first product into the clinic.
Arvinas Inc. (NASDAQ:ARVN) and Bayer AG (Xetra:BAYN) partnered to use Arvinas' Proteolysis Targeting Chimera (PROTAC) technology to develop protein degrader therapeutics against targets elected by Bayer for cardiovascular, gynecological and cancer immunotherapy applications. A PROTAC is a three-part compound consisting of one molecule that binds a target intracellular protein, a second molecule that tags the target protein for degradation by proteasomes in the cytosol, and a chemical linker connecting the two (see "Down the Hatch")...